These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2452959

  • 21. The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats.
    Terubayashi H, Akagi Y.
    Jpn J Ophthalmol; 1989; 33(3):343-7. PubMed ID: 2507812
    [Abstract] [Full Text] [Related]

  • 22. Prevention of defects of axonal transport in experimental diabetes by aldose reductase inhibitors.
    Tomlinson DR, Willars GB, Robinson JP.
    Drugs; 1986; 32 Suppl 2():15-8. PubMed ID: 2431858
    [Abstract] [Full Text] [Related]

  • 23. Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
    Daniels BS, Hostetter TH.
    Diabetes; 1989 Aug; 38(8):981-6. PubMed ID: 2502460
    [Abstract] [Full Text] [Related]

  • 24. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y, Fujimori S, Okada K.
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [Abstract] [Full Text] [Related]

  • 25. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE, Plurad SB, Sherman WR, Williamson JR, Tilton RG.
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [Abstract] [Full Text] [Related]

  • 26. No influence of an aldose reductase inhibitor on glycogen deposition in tubules from streptozotocin diabetic rats.
    Rasch R, Osterby R.
    J Diabet Complications; 1989 May; 3(4):198-201. PubMed ID: 2533211
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil.
    Phillips SA, Mirrlees D, Thornalley PJ.
    Biochem Pharmacol; 1993 Sep 01; 46(5):805-11. PubMed ID: 8373434
    [Abstract] [Full Text] [Related]

  • 29. The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats.
    Sochor M, Kunjara S, McLean P.
    Biochem Pharmacol; 1988 Sep 01; 37(17):3349-56. PubMed ID: 2969732
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A, Cruz E.
    Diabetes; 1985 Jan 01; 34(1):15-21. PubMed ID: 3917257
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ.
    Diabetes; 1990 Jun 01; 39(6):690-6. PubMed ID: 2140802
    [Abstract] [Full Text] [Related]

  • 34. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
    Tomlinson DR, Mayer JH.
    Exp Neurol; 1985 Aug 01; 89(2):420-7. PubMed ID: 2410289
    [Abstract] [Full Text] [Related]

  • 35. Effect of insulin and statil on aldose reductase expression in diabetic rats.
    Ghahary A, Chakrabarti S, Sima AA, Murphy LJ.
    Diabetes; 1991 Nov 01; 40(11):1391-6. PubMed ID: 1936600
    [Abstract] [Full Text] [Related]

  • 36. Increased steady-state levels of laminin B1 mRNA in kidneys of long-term streptozotocin-diabetic rats. No effect of an aldose reductase inhibitor.
    Poulsom R, Kurkinen M, Prockop DJ, Boot-Handford RP.
    J Biol Chem; 1988 Jul 25; 263(21):10072-6. PubMed ID: 2839472
    [Abstract] [Full Text] [Related]

  • 37. Antioxidant status in an in vitro model for hyperglycemic lens cataract formation: effect of aldose reductase inhibitor statil.
    Hothersall JS, Taylaur CE, McLean P.
    Biochem Med Metab Biol; 1988 Oct 25; 40(2):109-17. PubMed ID: 3142503
    [Abstract] [Full Text] [Related]

  • 38. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C, Dvornik D.
    Proc Soc Exp Biol Med; 1986 Sep 25; 182(4):505-10. PubMed ID: 3090558
    [Abstract] [Full Text] [Related]

  • 39. Nonosmotic diabetic cataracts.
    Malone JI, Lowitt S, Cook WR.
    Pediatr Res; 1990 Mar 25; 27(3):293-6. PubMed ID: 2138728
    [Abstract] [Full Text] [Related]

  • 40. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y.
    Metabolism; 1984 Mar 25; 33(3):212-4. PubMed ID: 6420645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.